Truffle Capital, an investor in Neovacs, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
-
Neovacs, a spin-off from Pierre & Marie Curie University, Paris, France, is a biotechnology company focused on immunology and oncology. The company is pioneering the next generation of antibody therapy.
-
Following a €6.1 million investment by Truffle Capital since 2003, Neovacs is actively pursuing its core programmes and recently closed a €13 million financing round led by the Novartis Venture Fund, the most prominent pharmaceutical corporate fund. Neovacs targets an IPO in 2009.
-
Truffle Capital board members: Philippe Pouletty, M.D., Anne-Elisabeth Chaumet-Riffaud, M.D.